



Integra LifeSciences Appoints Topaz Kirlaw Chief Regulatory Officer

Jul 2, 2026

Kirlaw will lead Integra's global regulatory affairs organization as the company continues to strengthen quality, compliance, and execution.

PRINCETON, N.J., July 02, 2026 (GLOBE NEWSWIRE) -- [Integra LifeSciences Holdings Corporation](#) (Nasdaq: IART), a global leader in medical technology, today announced the appointment of Topaz Kirlaw, DBA, MBA, as corporate vice president and chief regulatory officer. Kirlaw will lead Integra's global regulatory affairs organization and oversee regulatory strategy, compliance, submissions, and transformation initiatives worldwide.

Kirlaw served as the interim regulatory leader for the company over the past several months, leading the global regulatory organization during an important period for the company. In her interim capacity, she provided oversight of regulatory compliance, managed active submissions, and led risk mitigation efforts across the organization.

"Topaz brings deep regulatory experience, sound judgment, and a practical approach to helping the business move forward the right way," said Stuart Essig, chairman and chief executive officer of Integra LifeSciences. "She has earned the confidence of the leadership team, and I am pleased to have her in this role as we continue to strengthen our regulatory capabilities and advance our mission of restoring patients' lives."

Since joining Integra in 2021, Kirlaw has played a key role in building the company's regulatory capabilities and advancing key business priorities. She brings more than 35 years of healthcare and medical technology industry experience spanning regulatory affairs, quality, operations, and clinical functions.

Prior to joining Integra, Kirlaw held positions of increasing responsibility at several healthcare and medical technology organizations, including Danaher Corporation, Apyx Medical, Bio-Tissue, and the University of Miami's Diabetes Research Institute. She began her career as a clinical laboratory scientist, serving at leading healthcare institutions including the National Institutes of Health, Georgetown University Hospital, and the University of Maryland Medical Center.

Kirlaw earned a bachelor's degree in clinical laboratory science from Florida International University and holds a master's degree and a doctorate in business administration from Nova Southeastern University's School of Business and Entrepreneurship.

About Integra LifeSciences

Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies is trusted by healthcare professionals to deliver transformative care. For the latest news and information about Integra and its products, please visit www.integralife.com.

Investor Relations:

Chris Ward
(609) 772-7736
chris.ward@integralife.com

Media Contact:

Laurene Isip
(609) 208-8121
laurene.isip@integralife.com

A photo accompanying this announcement is available at <https://www.globenewswire.com/NewsRoom/AttachmentNg/1a23fae4-98d6-4910-9b3a-5172804e1e1c>

Topaz Kirlaw



Topaz Kirlaw, DBA, MBA appointed as corporate vice president and chief regulatory officer.